BUDESONIDE
| Brand name | ORTIKOS |
|---|---|
| Active ingredient | BUDESONIDE |
| Strength | 9MG |
| Dosage form | CAPSULE, DELAYED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | June 2019 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 10172802 | September 2036 | use U-2554 |
| 9707182 | September 2036 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.